Yes. GLP-1 receptor agonists are being studied as possible treatments for alcohol use disorder, but they are not currently FDA-approved for AUD. Early clinical trials suggest that drugs in this class may reduce some drinking outcomes or cravings in certain patients, but larger and longer studies are still needed before they can be considered established addiction treatments.
What are GLP-1 medications?
GLP-1 receptor agonists are medications originally developed for conditions such as type 2 diabetes and obesity. They affect appetite, metabolism, and brain pathways involved in reward and motivation, which has led researchers to study whether they might also influence alcohol use.
Why are researchers interested in GLP-1 drugs for alcohol use disorder?
Preclinical studies, observational data, and early clinical trials have suggested that GLP-1 signaling may affect alcohol reward and consumption. That biological rationale has led to randomized trials of medications such as semaglutide in people with alcohol use disorder.
What have human studies found so far?
A 2025 randomized trial of once-weekly semaglutide found reductions in some measures of alcohol consumption and craving compared with placebo. A separate 2026 randomized trial of oral semaglutide found reductions in heavy drinking days, drinks per drinking day, and naturalistic alcohol craving, although not every primary or secondary outcome improved.
NIH has also highlighted trial evidence suggesting that GLP-1 treatment combined with behavioral therapy may reduce heavy drinking in some adults with alcohol use disorder.
Are GLP-1 medications approved for alcohol use disorder?
No. GLP-1 medications such as semaglutide are not FDA-approved specifically to treat alcohol use disorder. Using them for AUD would therefore be off-label, and current evidence is not strong enough to replace established treatments.
What treatments are already approved for alcohol use disorder?
FDA-approved medications for AUD include naltrexone, acamprosate, and disulfiram. Behavioral therapies and recovery-support approaches can also be important parts of treatment.
Trinity has a separate guide on medications used to treat alcohol use disorder.
What questions remain about GLP-1 medications and alcohol?
Researchers still need to understand which patients are most likely to benefit, how durable the effects are, how these medications compare with established AUD medications, what role behavioral therapy should play, and how safety considerations affect treatment decisions.
Does Trinity Behavioral Health offer GLP-1 treatment for AUD?
This educational article does not establish that Trinity offers or prescribes GLP-1 medications for alcohol use disorder. Current treatment options should be confirmed directly with the clinical team.
Frequently asked questions
Is semaglutide an approved alcohol-treatment medication?
No. It is being studied for AUD but is not FDA-approved for that indication.
Do early trials show promise?
Yes, some early randomized trials have reported reductions in selected drinking or craving outcomes, but the evidence remains preliminary.
Should someone switch from an approved AUD medication to a GLP-1 drug?
That decision cannot be made from general research findings. Medication choices should be individualized by a qualified clinician.
Sources
- PubMed: Once-Weekly Semaglutide in Adults With Alcohol Use Disorder
- PubMed: Oral Semaglutide for Alcohol Use Disorder—Randomized Clinical Trial
- NIH: GLP-1 Plus Therapy Can Reduce Heavy Drinking
This article discusses emerging research and is not individualized medical advice.